Category Archives: TRIPS

Draft Pharmaceutical Policy, 2017

Source: All India Drug Action Network (AIDAN) The Department of Pharmaceuticals has circulated a Draft Pharmaceutical Policy, 2017 which can be accessed here. The draft policy identifies the following key objectives: a. Making essential drugs accessible at affordable prices to the … Continue reading

Posted in API, Biologics/Biosimilars, Evergreening, Innovation, IPR, Patent, R&D, Uncategorized | Leave a comment

South African IP policy draft released seeking comments from public

International Trade and Economic Development division of South African Government has released the  Draft Intellectual Property Policy of the Republic of south Africa Phase 2017 and it is now publicly available for comments.  Access the draft policy here: http://www.dti.gov.za/gazzettes/IP_Policy.pdf   

Posted in IPR, R&D, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

Stakeholder Intervention at 19th RCEP negotiations round- Chalermsak Kittitrakul, network of PLHIV & AIDS, Peoples’ Health Systems Movement, and FTA Watch

Thai CSOs’ comments on the data exclusivity measure in the RCEP given at the stakeholder consultation meeting hosted by the RCEP trade negotiators at Hyderabad, India on July 25, 2017. Good afternoon, trade negotiators of the ASEAN countries and the … Continue reading

Posted in Data Exclusivity, IPR, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

What’s at stake in Hyderabad

By Feroz Ali, The Hindu | July 28, 2017 India must counter Japan’s U.S.-style pressure at the RCEP talks and ensure affordable generic medicines Leaked texts are like leaked gases — you may never find the one responsible for it, … Continue reading

Posted in Data Exclusivity, IP Rights, IPR, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, Uncategorized | Leave a comment

No logic in extending length of patents

Granting a longer term for pharmaceutical patents will result in delays in the entry of generic versions and could adversely affect access to medicines   By Feroz Ali, Live Mint | July 28, 2017 A proposal to further extend the … Continue reading

Posted in Biologics/Biosimilars, Data Exclusivity, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

Stakeholder Intervention at 19th RCEP negotiations round- James Love, Knowledge Ecology International

These are the notes I used when providing the KEI comments at the July 25, 2017 civil society stakeholder forum at the 19th round of the RCEP negotiation. My name is James Love. I work for Knowledge Ecology International, an … Continue reading

Posted in Delinkage, FTA, IPR, Patent, R&D, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

Trading away health

By Rohit Malpani, The Hindu | July 23, 2017 Hyderabad, well known as the hub of the Indian pharmaceuticals industry, ranks third globally in terms of its production volume, with a turnover of Rs. 18 billion a year. Most of … Continue reading

Posted in Data Exclusivity, FTA, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, Uncategorized | Leave a comment